Serum soluble tumour necrosis factor receptor type I concentrations independently predict prognosis in patients with breast cancer

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 10, 2010, Pages 1481-1486

  Fuksiewicz, Malgorzata ^a   Kowalska, Maria ^a   Kotowicz, Beata ^a   Rubach, Maryna ^a   Chechlinska, Magdalena ^a   Pienkowski, Tadeusz ^a   Kaminska, Janina ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

breast cancer; cytokine; prognosis; soluble tumour necrosis factor receptor type I (sTNF RI)

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; ESTROGEN RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER STAGING; CASE REPORT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CYTOKINES; FEMALE; FIBROBLAST GROWTH FACTOR 2; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SENSITIVITY AND SPECIFICITY; SOLUBILITY; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77958177045     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.278     Document Type: Article

References (30)

1. Kaminska J, Nowacki MP, Kowalska M, Rysińska A, Chwaliński M, Fuksiewicz M, et al. Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I - an independent prognostic factor. Tumor Biol 2005;26:186-94.
2. Karczewska A, Nawrocki S, Breborowicz D, Filas V, Mackiewicz A. Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients breast carcinoma. Cancer 2000;88:2061-71.
3. Kamińska J, Kowalska M, Kotowicz B, Fuksiewicz M, Głogowski M, Wójcik E, et al. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. Oncology 2006;70:115-25.
4. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 2003;88:1721-6.
5. Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev 2006;17:325-37.
6. Chechlinska M, Kowalska M, Kaminska J. Cytokines as potential tumour markers. Expert Opin Med Diagn 2008;2:691-711.
7. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6.
8. Nam RK, Trachtenberg J, Jewett MA, Toi A, Evans A, Emami M, et al. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:1270-3.
9. Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, et al. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 2003;63:3991-4.
10. Marszalek M, Wachter J, Ponholzer A, Leitha T, Rauchenwald M, Madersbacher S. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls. Eur Urol 2005;48:34-9.
11. Freund A, Chauveau C, Brouillet G, Lucas A, Lacroix M, Licznar A, et al. IL-8 expression and its possible relationship with oestrogen-receptor-negative status of breast cancer cells. Oncogene 2003;22:256-65.
12. Sheen-Chen SM, Chou FF, Hsu W, Huang CC, Eng HL, Tang RP. Lack of prognostic value of insulin-like growth factor-1 in patients with breast cancer: analysis with tissue microarray. Anticancer Res 2007;27:3541-4.
13. Rao VS, Dyer CE, Jameel JK, Drew PJ, Greenman J. Potential prognostic and therapeutic roles for cytokines in breast cancer. Oncol Rep 2006;15:179-85.
14. Fuksiewicz M, Kaminska J, Kotowicz B, Kowalska M, Rubach M, Pienkowski T. Serum cytokine levels and the expression of oestrogen and progesterone receptors in breast cancer patients. Clin Chem Lab Med 2006;9:1092-7.
15. Pichon MF, Moulin G, Pallud C, Pecking A, Floiras JL. Serum bFGF (basic fibroblast growth factor) and CA 15.3 in the monitoring of breast cancer patients. Anticancer Res 2000;20:1189-94.
16. Kozlowski L, Zakrzewska I, Tokajuk P, Wojtkiewicz MZ. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst 2003;48:82-4.
17. Byrne GJ, McDowell G, Agarawal R, Sinha G, Kumar S, Bundred NJ. Serum vascular endothelial growth factor in breast cancer. Anticancer Res 2007;27:3481-7.
18. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 2001;7:285-9.
19. Obermair A, Kucera E, Mayerhofer K, Speiser P, Seifert M, Czerwenka K, et al. Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival. Int J Cancer 1997;74:455-8.
20. Aderka D, Engelmann H, Hornik V, Skornick Y, Levo Y, Wallach D, et al. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 1991;51:5602-7.
21. Wu Y, Saldana L, Chillar R, Vadgama JV. Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment. Int J Oncol 2002;20:509-16.
22. Rutkowski P, Kamińska J, Kowalska M, Ruka W, Steffen J. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol 2003;84:151-9.
23. Voorzanger-Rousselot N, Garnero P. Biochemical markers in oncology. Part I: molecular basis. Part II: Clinical uses. Cancer Treat Rev 2007;33:230-83.
24. Benoy IH, Salgado R, Van Dam P, Weyler J, Van Marck E, Scharpé S, et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004;10:7157-62.
25. Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL, Rimm DL. Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res 2004;10:173-7.
26. Llanes-Fernandez L, Alvarez-Goyanes RT, Arango-Prado Mdel C, Alcocer-González JM, Mojarrieta JC, Pérez XE, et al. Relationship between IL-10 and tumor markers in breast cancer patients. Breast 2006;15:482-9.
27. Ruka W, Rutkowski P, Kaminska J, Rysinska A, Steffen J. Alternations of routine blood tests in adult patients with soft tissue sarcomas: Relationships to cytokine serum levels and prognostic significance. Ann Oncol 2001;12:1423-32.
28. Gaducci A, Ferdeghini M, Castellani C, Annicchiarico C, Gagetti O, Prontera C, et al. Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55-and 75-kDa s TNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer. Gynecol Oncol 1995;58:184-8.
29. Gupta S. Tumor necrosis factor-alpha-induced apoptosis in T cells from aged humans: a role of TNFR-I and downstream signalling molecules. Exp Gerontol 2002;37:293-9.
30. Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer. Ann Oncol 2008;19:1340-6.